Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
about
Immunotherapy for cancer in the central nervous system: Current and future directionsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Cancer Immunotherapy for Gliomas: Overview and Future DirectionsSyndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.Tumor Vaccines for Malignant Gliomas.
P2860
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@en
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@nl
type
label
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@en
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@nl
prefLabel
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@en
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@nl
P2093
P2860
P1476
Wilms tumor 1 peptide vaccinat ...... act on immunological response.
@en
P2093
Akihiro Tsuboi
Haruo Sugiyama
Hiroko Nakajima
Junichi Sakamoto
Naoki Hosen
Naoki Kagawa
Naoya Hashimoto
Norio Arita
Noriyuki Kijima
Satoshi Morita
P2860
P2888
P304
P356
10.1007/S00262-015-1674-8
P577
2015-03-14T00:00:00Z